Original Research
Accepted on 13 Feb 2026
Real-world outcomes after switching from standard therapy to efgartigimod in five patients with chronic inflammatory demyelinating polyradiculoneuropathy: a case series study in Japan
in Neuromuscular Disorders and Peripheral Neuropathies